GBB
AI Biomedical R&D Company
Hong Kong
May 20, 2026
Great Bay Bio (referred to as "GBB") announced today the signing of a strategic cooperation agreement with a global leading biosimilar company to establish a long-term, future-oriented, in-depth partnership.This collaboration will combine GBB's AI-driven targeted integration cell line development platform, AlfaCell, with the leading biosimilar company’s complete industrial chain covering early R&D, clinical, registration, production, and global direct sales, jointly providing end-to-end integrated services from cell line construction to preclinical development and commercialization. This is another significant milestone in GBB's global strategic layout, which will accelerate the commercial application of AlfaCell platform technologies in global biosimilars, innovative biologics, and other fields, working hand-in-hand with industry partners to offer a one-stop solution for the entire process from drug discovery to preclinical development for the global biopharmaceutical industry.
GBB's AlfaCell, as the world's first commercially available targeted integration cell line development platform, boasts unique "dual speed" and "high expression" advantages:Complete the RCB work cycle in 1.5 months, which traditionally takes 6 months, and quickly predict product quality within 1 month, accelerating process development decisions and CMC development progress; the average expression level of platform customer projects exceeds 6.9g/L, achieving breakthrough progress in the field of complex molecule development, especially suitable for the development of cutting-edge biopharmaceuticals such as bispecific antibodies, multi-specific antibodies, and ADCs — monoclonal antibody expression levels up to 15g/L, bispecific antibodies up to 12g/L (correct pairing rate generally >80%), and nanobodies up to 13g/L.
The pharmaceutical company involved in this cooperation is a global Top 5 biosimilar company and the top pharmaceutical enterprise in the Asia-Pacific region, being an international leading biopharmaceutical leader that integrates the entire industrial chain of R&D, production, and sales.Core products cover major disease areas such as autoimmune diseases, oncology, and ophthalmology, and have been approved for marketing in nearly 100 countries and regions worldwide. Relying on ultra-large production capacity, a complete全产业链 layout, and mature global registration and submission capabilities, the company firmly ranks among the top tier of global biosimilars, leading the industry in global market share. The business spans all aspects, including early-stage R&D, clinical development, global registration, large-scale production, and international direct sales, demonstrating exceptionally strong global commercialization capabilities.
The strong alliance between the two parties this time represents a complementary and mutually empowering collaboration, integrating AI-based targeted cell line development technology platforms with the strengths of the world's top biopharmaceutical leaders.GBB efficiently addresses industry pain points such as long cell line development cycles, low expression levels, unstable quality, and challenges in complex molecule pairing through the AlfaCell platform, accelerating and enhancing the efficacy of its partners' products. Partners, leveraging their global production, registration, and commercialization networks, facilitate the rapid international expansion of AlfaCell technology, covering more biopharmaceutical R&D projects worldwide. Both parties will collaborate to shorten the global new drug R&D cycle, reduce development costs, and help more high-quality biologics benefit patients globally, injecting strong momentum into the high-quality development of the global biopharmaceuticals industry.
END
Great Bay Bio Establishes Strategic Partnership with a Global Leading Biosimilar Enterprise to Accelerate Global Adoption of AlfaCell Platform
Hong Kong
May 20, 2026
Today, Great Bay Bio (GBB) announced the signing of a strategic cooperation agreement with a globally leading biosimilar enterprise to build a long‑term, forward‑looking in‑depth partnership. This collaboration integrates GBB’s AI‑powered site‑specific integration cell line development platform AlfaCell with the partner’s comprehensive industrial chain covering early‑stage R&D, clinical development, regulatory registration, manufacturing and global direct sales. Both parties will jointly provide end‑to‑end integrated services ranging from cell line construction to pre‑clinical development and commercialization. Marking another key milestone in GBB’s global expansion strategy, this partnership will accelerate the commercial rollout of AlfaCell technologies across global biosimilar and novel biotherapeutic segments. Together with industry partners, it will deliver one‑stop full‑stream solutions from target discovery to pre‑clinical development for the global biopharmaceutical sector.
As the world’s first commercialized site‑specific integration cell line development platform, AlfaCell features unique strengths of dual speediness and high productivity: it achieves RCB generation in just 1.5 months, compared with the 6‑month cycle of conventional methods, and enables early prediction of product quality within one month to streamline process development decisions and advance CMC progress. The platform delivers an average titer of over 6.9 g/L across customer projects and achieves breakthroughs in complex molecule development, especially for cutting‑edge biotherapeutics including bispecific antibodies, multispecific antibodies and ADCs. It supports titers up to 15 g/L for mAbs, 12 g/L for BsAbs (with correct pairing rates generally above 80%), and 13 g/L for nanobodies.
The partnered enterprise ranks among the world’s top‑5 biosimilar developers and top pharmaceutical companies in the Asia‑Pacific region. As a world‑class integrated biopharma leader covering R&D, manufacturing and commercialization, its core products target major disease areas including autoimmune disorders, oncology and ophthalmology, with approvals in nearly 100 countries and regions worldwide. Backed by ultra‑large production capacity, a full‑value‑chain layout and proven global regulatory expertise, the company is firmly positioned in the global top tier of biosimilar developers with leading market share. Its business spans early‑stage research, clinical trials, global registration, large‑scale manufacturing and international direct sales, enabling robust global commercialization capabilities.
This powerful alliance realizes complementary strengths and mutual empowerment between GBB’s AI‑driven site‑specific integration cell line development platform and the world‑class biopharma leader. AlfaCell efficiently addresses core industry pain points such as lengthy cell line development cycles, low productivity, unstable product quality and difficult pairing of complex molecules, accelerating the partner’s pipeline development and boosting efficiency. In return, the partner leverages its global manufacturing, regulatory and commercial networks to accelerate the international expansion of AlfaCell technologies for wider global biopharma R&D projects.
Jointly, both parties will shorten global new drug development timelines, cut R&D costs, bring more high‑quality biotherapeutics to patients worldwide, and inject strong momentum into the high‑quality development of the global biopharmaceutical industry.
END